株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ブドウ膜悪性黒色腫:パイプライン製品の分析

Uveal Melanoma - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 302507
出版日 ページ情報 英文 108 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
ブドウ膜悪性黒色腫:パイプライン製品の分析 Uveal Melanoma - Pipeline Review, H2 2016
出版日: 2016年09月21日 ページ情報: 英文 108 Pages
概要

ブドウ膜悪性黒色腫は、最もよく見られる眼球内腫瘍で、癌(悪性)細胞がブドウ膜と呼ばれる眼球部分に見られる疾患です。ブドウ膜には、メラニンを形成する細胞(メラノサイト)が含まれています。このメラニン細胞が癌化すると、メラノーマと呼ばれます。症状には、虹彩上の暗斑、緑内障、眼痛、眼の赤みなどが含まれます。

当レポートでは、ブドウ膜悪性黒色腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

ブドウ膜悪性黒色腫の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

ブドウ膜悪性黒色腫:企業で開発中の治療薬

ブドウ膜悪性黒色腫:大学/機関で研究中の治療薬

ブドウ膜悪性黒色腫:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

ブドウ膜悪性黒色腫:企業で開発中の製品

ブドウ膜悪性黒色腫:大学/機関で研究中の製品

ブドウ膜悪性黒色腫の治療薬開発に従事している企業

  • Aura Biosciences, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Celldex Therapeutics, Inc.
  • Cleveland BioLabs, Inc.
  • Eli Lilly and Company
  • Immunocore Limited
  • Navigen Pharmaceuticals, Inc.
  • Novartis AG
  • PEP-Therapy SAS
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.

ブドウ膜悪性黒色腫:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

ブドウ膜悪性黒色腫:最近のパイプライン動向

ブドウ膜悪性黒色腫:休止中のプロジェクト

ブドウ膜悪性黒色腫:開発が中止された製品

ブドウ膜悪性黒色腫:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8485IDB

Summary

Global Markets Direct's, 'Uveal Melanoma - Pipeline Review, H2 2016', provides an overview of the Uveal Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Uveal Melanoma
  • The report reviews pipeline therapeutics for Uveal Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Uveal Melanoma therapeutics and enlists all their major and minor projects
  • The report assesses Uveal Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Uveal Melanoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Uveal Melanoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Uveal Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Uveal Melanoma Overview
  • Therapeutics Development
    • Pipeline Products for Uveal Melanoma - Overview
    • Pipeline Products for Uveal Melanoma - Comparative Analysis
  • Uveal Melanoma - Therapeutics under Development by Companies
  • Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes
  • Uveal Melanoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Uveal Melanoma - Products under Development by Companies
  • Uveal Melanoma - Products under Investigation by Universities/Institutes
  • Uveal Melanoma - Companies Involved in Therapeutics Development
    • Aura Biosciences, Inc.
    • Bellicum Pharmaceuticals, Inc.
    • Celldex Therapeutics, Inc.
    • Cleveland BioLabs, Inc.
    • Eli Lilly and Company
    • Iconic Therapeutics, Inc.
    • Immunocore Limited
    • Navigen Pharmaceuticals, Inc.
    • Novartis AG
    • PEP-Therapy SAS
    • Pfizer Inc.
    • Spectrum Pharmaceuticals, Inc.
  • Uveal Melanoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AU-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPX-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crizotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DPTC-9h - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emibetuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glembatumumab vedotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hI-con1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPH-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPH-211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMCgp-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KCN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LXS-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • merestinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAV-2729 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nutlin-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sotrastaurin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sunitinib malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine 2 for Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vincristine sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Uveal Melanoma - Dormant Projects
  • Uveal Melanoma - Discontinued Products
  • Uveal Melanoma - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016
      • Mar 30, 2016: Immunocore's IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
      • Jan 25, 2016: Immunocore's IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma
      • Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC
      • Sep 09, 2015: Immunocore's IMCgp100 Accepted for Adaptive Pathway Pilot Programme
      • Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma
      • May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences' Novel Treatment for Uveal Melanoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Uveal Melanoma, H2 2016
  • Number of Products under Development for Uveal Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Uveal Melanoma - Pipeline by Aura Biosciences, Inc., H2 2016
  • Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
  • Uveal Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Uveal Melanoma - Pipeline by Cleveland BioLabs, Inc., H2 2016
  • Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2016
  • Uveal Melanoma - Pipeline by Iconic Therapeutics, Inc., H2 2016
  • Uveal Melanoma - Pipeline by Immunocore Limited, H2 2016
  • Uveal Melanoma - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
  • Uveal Melanoma - Pipeline by Novartis AG, H2 2016
  • Uveal Melanoma - Pipeline by PEP-Therapy SAS, H2 2016
  • Uveal Melanoma - Pipeline by Pfizer Inc., H2 2016
  • Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Uveal Melanoma - Dormant Projects, H2 2016
  • Uveal Melanoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Uveal Melanoma, H2 2016
  • Number of Products under Development for Uveal Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top